Shares of Delcath Systems Inc. (Nasdaq: DCTH) fell more than 40% yesterday after U.S. Food and Drug Administration (FDA) staffers said the company's experimental liver-cancer-treatment system would probably require another round of clinical trials. The surprise recommendation was contained in a briefing document that was posted yesterday on the FDA's Web site. The document outlines […]
Archives for May 2013
May 2013 - Page 20 of 20 - Money Morning - Only the News You Can Profit From
Jim Rogers on Investing in Gold 2013
Money Morning Executive Editor William Patalon III recently had a chance to catch up with famed investor Jim Rogers on investing in gold, U.S. stocks, and the best commodities for 2013.
Renowned commodities investor Rogers is concerned about the worldwide economy, but he's not worried about the recent sell off in gold.
In fact, he stands poised to pounce on the yellow metal should it fall further.
To continue reading, please click here...
UDR Meets Earnings, Revs Up - Analyst Blog
UDR Inc. (UDR) – a real estate investment trust (REIT) – reported first-quarter 2013 FFO (funds from operations), excluding non-recurring items, of 34 cents per share. The result came in line with both the Zacks Consensus Estimate as well as the year-ago quarter figure. Although, higher revenues aided the quarterly results, flat physical occupancy level […]
Texas Roadhouse Beats 1Q Earnings, Rev - Analyst Blog
Restaurateur Texas Roadhouse Inc.’s (TXRH) first-quarter 2013 adjusted earnings of 37 cents per share beat the Zacks Consensus Estimate of 35 cents by 5.7% and the prior-year earnings per share of 31 cents by 19.8%. Increased revenues along with efficient cost containment resulted in the increase in earnings. Total revenue climbed 11.0% from the prior-year […]
The Untold Truth About Solar Stocks
The price of solar energy shares has been spiking, leading to the obvious parallel questions:
Is it sustainable?…Or what prospects exist for the average individual retail investor?
Before we address these questions, it would be best to lay some groundwork.
The increase in solar share prices has been just about across the board. This is most clearly seen in the rise in solar and related exchange traded funds (ETF). Guggenheim Solar (NYSEArca: TAN) has advanced 24.8% this past month, while American Vector Solar Energy ETF (NYSEArca: KWT) is up 15.2%. The iShares S&P Global Clean Energy Index (NasadqGM: ICLN) has improved 11.8%.
However, before you rush out and buy any of these ETFs, consider the longer view.
From December 1, 2012, TAN is down 36%, KWT is off 34.9%, and ICLN is weaker by 10.7%. The recent push up has resulted in some – apparently – better solar plays. Yet the medium-term perspective indicates the run up might not last.
Here's why…
Check Out Who's Hiding $32 Trillion in Offshore Accounts
More than two million emails that shed light on the biggest tax dodge in history – trillions of dollars hidden in offshore accounts – have been uncovered by the British newspaper The Guardian and the Washington, D.C.-based International Consortium of Investigative Journalists (ICIJ).
Some $32 trillion has been hidden in small island banking hubs which host a bevy of trust funds, shell corporations and other tax havens, the Tax Justice Network estimates.
This money is to the financial world what the Higgs boson and dark matter are to particle physics: It's tough to prove it's there, but the universe doesn't make much sense without it. It's just a matter of connecting the money to the people hiding it.
That's been a tall order… until now.
Has Sequestration Saved the U.S. Economy?
There's a Jamaican saying, "the higher the monkey climbs up the tree, the more his butt is exposed."
The point being that the more we rise, the more vulnerable we become.
That has truly come to pass for a pair of superstars of the dismal science. And it could have a big impact on how successfully (or unsuccessfully) we can get the U.S. economy back on the rails.
This is What Happened With Delcath
Shares of Delcath Systems Inc. (Nasdaq: DCTH) fell more than 40% yesterday after U.S. Food and Drug Administration (FDA) staffers said the company's experimental liver-cancer-treatment system would probably require another round of clinical trials. The surprise recommendation was contained in a briefing document that was posted yesterday on the FDA's Web site. The document outlines […]